Aerie Pharmaceuticals Stock Jumps on FDA Drug Approval

A number of call traders bought options in previous sessions

Mar 13, 2019 at 9:29 AM
facebook X logo linkedin

Aerie Pharmaceuticals Inc (NASDAQ:AERI) is trading up 7.8% this morning at $49.38, after the company said the Food and Drug Administration (FDA) approved Rocklatan, a treatment for glaucoma patients. This will be the second drug to hit the market for AERI, and an analyst at Stifel expects FDA approval for Rocklatan to provide a boost to Aerie's revenues.

Today's price action puts the shares above the 32-week moving average for the first time since October. This trendline, along with the $48 level, has been acting as a ceiling in recent weeks. Aerie Pharmaceuticals stock suffered heavy selling in the second half of 2018, falling from a July record high of $74.75 to December's low of $32.18.

Today's gains could be good news for options traders. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows more than five calls were bought to open for every put during the past 10 days. The March 50 call saw the largest increase in open interest during this time span, and buy-to-open activity was confirmed here. The March 55 and April 50 calls were also popular.

Meanwhile, there was recently a sharp decline in short interest on AERI, with the number of shorted sales fall 23% in the last two reporting periods. But with almost 12% of the float still held by these bears, there's potential for more short covering going forward.

Analysts are certainly on board. That is, six of the seven brokerage firms in coverage have "buy" or "strong buy" recommendations, and there are zero "sells" on the books. Even more telling is the average 12-month price target from this group, which stands all the way up at $80.70.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI